Therapy Area
FDA drug dosage optimisation guidelines signal clinical trial reform
The FDA chooses drug optimisation as the preferred blueprint for cancer trials, departing from the maximum tolerated dose model.
Kangpu concludes subject enrolment in SLE therapy trial
Shaping AML treatment: how menin inhibitors are changing the game
Pfizer and Astellas report positive data from prostate cancer therapy trial
Childhood and young adult obesity increased risk of later thromboembolic events
Cognition to commence Phase II trial of dry AMD drug candidate
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
